JP2008537874A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008537874A5 JP2008537874A5 JP2007533727A JP2007533727A JP2008537874A5 JP 2008537874 A5 JP2008537874 A5 JP 2008537874A5 JP 2007533727 A JP2007533727 A JP 2007533727A JP 2007533727 A JP2007533727 A JP 2007533727A JP 2008537874 A5 JP2008537874 A5 JP 2008537874A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- polynucleotide
- cell line
- rage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims 22
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 108010005094 Advanced Glycation End Products Proteins 0.000 claims 2
- 102100029599 Advanced glycosylation end product-specific receptor Human genes 0.000 claims 2
- 101001061840 Homo sapiens Advanced glycosylation end product-specific receptor Proteins 0.000 claims 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 229930183010 Amphotericin Natural products 0.000 claims 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 claims 1
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims 1
- 229940009444 amphotericin Drugs 0.000 claims 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 230000005951 type IV hypersensitivity Effects 0.000 claims 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61324704P | 2004-09-27 | 2004-09-27 | |
| PCT/US2005/034502 WO2006036922A2 (en) | 2004-09-27 | 2005-09-27 | Srage mimetibody, compositions, methods and uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008537874A JP2008537874A (ja) | 2008-10-02 |
| JP2008537874A5 true JP2008537874A5 (enExample) | 2008-11-13 |
Family
ID=36119514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007533727A Pending JP2008537874A (ja) | 2004-09-27 | 2005-09-27 | ｓＲＡＧＥミメティボディ、組成物、方法および使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20060084145A1 (enExample) |
| EP (1) | EP1799700A4 (enExample) |
| JP (1) | JP2008537874A (enExample) |
| AU (1) | AU2005289594B2 (enExample) |
| CA (1) | CA2581505A1 (enExample) |
| WO (1) | WO2006036922A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0406606A (pt) * | 2003-11-13 | 2005-12-06 | Hanmi Pharm Ind Co Ltd | Composição farmacêutica compreendendo uma região fc de imunoglobulina como um veìculo |
| CA2575830A1 (en) * | 2004-08-03 | 2006-02-16 | Transtech Pharma, Inc. | Rage fusion proteins and methods of use |
| MX2007001559A (es) * | 2004-08-03 | 2007-04-10 | Transtech Pharma Inc | Proteinas de fusion de receptor para productos finales glicados avanzados y metodos de uso. |
| US7790671B2 (en) * | 2005-10-07 | 2010-09-07 | Codman & Shurtleff, Inc. | Implantable pump for protein delivery for obesity control by drug infusion into the brain |
| WO2007067828A2 (en) * | 2005-10-24 | 2007-06-14 | Centocor, Inc. | Glp-2 mimetibodies, polypeptides, compositions, methods and uses |
| EP1963786B1 (en) * | 2005-12-23 | 2013-07-24 | GCoder Systems AB | Positioning pattern |
| CN101410411A (zh) * | 2006-02-09 | 2009-04-15 | 转化技术制药公司 | Rage融合蛋白及使用方法 |
| SG171670A1 (en) * | 2006-05-05 | 2011-06-29 | Transtech Pharma Inc | Rage fusion proteins, formulations, and methods of use thereof |
| JP4933159B2 (ja) * | 2006-06-02 | 2012-05-16 | 国立大学法人金沢大学 | アルツハイマー病の診断方法 |
| WO2008100470A2 (en) * | 2007-02-15 | 2008-08-21 | Transtech Pharma, Inc. | Rage - immunoglobulin fusion proteins |
| ES2564634T3 (es) | 2007-06-14 | 2016-03-28 | Galactica Pharmaceuticals, Inc. | Proteínas de fusión de RAGE |
| ES2537580T3 (es) | 2007-09-04 | 2015-06-09 | Compugen Ltd. | Polipéptidos y polinucleótidos, y usos de los mismos como una diana farmacológica para producir fármacos y agentes biológicos |
| EP2421892A1 (en) | 2009-04-20 | 2012-02-29 | Pfizer Inc. | Control of protein glycosylation and compositions and methods relating thereto |
| WO2012061448A1 (en) | 2010-11-04 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Anti-il-23 antibodies |
| EP2726503B1 (en) | 2011-06-30 | 2019-09-04 | Compugen Ltd. | Polypeptides and uses thereof for treatment of autoimmune disorders and infection |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| WO2013075027A2 (en) * | 2011-11-17 | 2013-05-23 | Emergent Product Development Seattle, Llc | Anti-sil6xr complex binding domains and methods of use |
| KR20140126357A (ko) | 2012-02-01 | 2014-10-30 | 컴퓨젠 엘티디. | C1orf32 항체 및 이의 암 치료를 위한 용도 |
| US11078265B2 (en) | 2012-05-03 | 2021-08-03 | Boehringer Ingelheim International Gmbh | Anti-IL-23 antibodies |
| ES2684549T3 (es) * | 2012-09-12 | 2018-10-03 | Genzyme Corporation | Polipéptidos que contienen Fc con glicosilación alterada y función efectora reducida |
| US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
| KR102420934B1 (ko) | 2013-03-11 | 2022-07-15 | 젠자임 코포레이션 | 과글리코실화된 결합 폴리펩티드 |
| KR101895634B1 (ko) | 2013-05-31 | 2018-09-05 | 한미약품 주식회사 | 변이된 힌지 영역을 포함하는 IgG4 Fc 단편 |
| EP4640239A2 (en) | 2014-03-19 | 2025-10-29 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
| WO2016014775A1 (en) | 2014-07-24 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Biomarkers useful in the treatment of il-23a related diseases |
| WO2016036918A1 (en) | 2014-09-03 | 2016-03-10 | Boehringer Ingelheim International Gmbh | Compound targeting il-23a and tnf-alpha and uses thereof |
| BR112017014684A2 (en) | 2015-02-04 | 2018-01-09 | Boehringer Ingelheim International Gmbh | methods of treatment of inflammatory diseases |
| JP2020519306A (ja) * | 2017-04-26 | 2020-07-02 | エヌセイジ コーポレーション | ｓＲＡＧＥを分泌する幹細胞を含むアルツハイマー病の予防または治療用薬学組成物 |
| EP3849578A4 (en) | 2018-09-14 | 2022-06-22 | Bioage Labs, Inc. | Rage fusion proteins with improved stability and ligand binding affinity and uses thereof |
| EP3947458A1 (en) | 2019-04-03 | 2022-02-09 | Genzyme Corporation | Anti-alpha beta tcr binding polypeptides with reduced fragmentation |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5202424A (en) * | 1984-03-19 | 1993-04-13 | The Rockefeller University | Mesangial cell-derived receptors for advanced glycosylation endproducts and uses thereof |
| US5585344A (en) * | 1984-03-19 | 1996-12-17 | The Rockefeller University | Liver-derived receptors for advanced glycosylation endproducts and uses thereof |
| US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
| WO1993004086A1 (en) | 1991-08-23 | 1993-03-04 | The Rockefeller University | Receptors for advanced glycosylation endproducts and uses thereof |
| US5864018A (en) * | 1996-04-16 | 1999-01-26 | Schering Aktiengesellschaft | Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor |
| WO1997039121A1 (en) | 1996-04-16 | 1997-10-23 | Schering Aktiengesellschaft | Advanced glycosylation end-product receptor peptides and uses therefor |
| US6790443B2 (en) | 1996-11-22 | 2004-09-14 | The Trustees Of Columbia University In The City Of New York | Method for treating symptoms of diabetes |
| US6555651B2 (en) | 1997-10-09 | 2003-04-29 | The Trustees Of Columbia University In The City Of New York | Ligand binding site of rage and uses thereof |
| US6004958A (en) * | 1997-02-05 | 1999-12-21 | Fox Chase Cancer Center | Compounds and methods for therapeutic intervention in preventing diabetic complications and procedures for assessing a diabetic's risk of developing complications and determining the efficacy of therapeutic intervention |
| US7101838B2 (en) | 1997-08-05 | 2006-09-05 | The Trustees Of Columbia University In The City Of New York | Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts |
| US6465422B1 (en) | 1998-04-17 | 2002-10-15 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting tumor invasion or spreading in a subject |
| US6753150B2 (en) * | 1998-10-05 | 2004-06-22 | The Trustees Of Columbia University In The City Of New York | Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6908741B1 (en) | 2000-05-30 | 2005-06-21 | Transtech Pharma, Inc. | Methods to identify compounds that modulate RAGE |
| US6613801B2 (en) | 2000-05-30 | 2003-09-02 | Transtech Pharma, Inc. | Method for the synthesis of compounds of formula I and their uses thereof |
| US6563015B1 (en) * | 2000-08-14 | 2003-05-13 | The Trustees Of Columbia University In The City Of New York | Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) and mutant APP in brain and uses thereof |
| US6825164B1 (en) * | 2000-08-14 | 2004-11-30 | The Trustees Of Columbia University In The City Of New York | Method to increase cerebral blood flow in amyloid angiopathy |
| CA2705366A1 (en) * | 2000-08-28 | 2002-03-07 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer |
| US20030166063A1 (en) * | 2001-03-05 | 2003-09-04 | Harris Robert B. | High level insect expression of rage proteins |
| JP3837494B2 (ja) * | 2001-03-19 | 2006-10-25 | 国立大学法人金沢大学 | 可溶型ｒａｇｅタンパク質 |
| WO2003008446A1 (en) * | 2001-07-19 | 2003-01-30 | Mitsubishi Pharma Corporation | Polypeptides relating to signal transfer of advanced glycation end product receptor |
| US6900292B2 (en) * | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| GB2379360A (en) * | 2001-08-31 | 2003-03-05 | Marconi Comm Ltd | Transmission of a MAP message from an MSC to an SCP |
| EP1572079A4 (en) | 2002-03-29 | 2006-09-06 | Centocor Inc | MAMMAL-CDR MIMETIC BODIES, COMPOSITIONS, PROCESSES AND APPLICATION PURPOSES |
| JP2006504406A (ja) * | 2002-06-28 | 2006-02-09 | セントカー・インコーポレーテツド | 哺乳動物のｃｈ１欠失ミメティボディ、組成物、方法および使用 |
| EP1575499A2 (en) * | 2002-06-28 | 2005-09-21 | Centocor, Inc. | Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| CN1774445A (zh) * | 2002-08-16 | 2006-05-17 | 惠氏公司 | 用于治疗rage相关病症的组合物和方法 |
| WO2004100890A2 (en) * | 2003-05-09 | 2004-11-25 | The Trustees Of Columbia University In The City Of New York | Rage g82s-related methods and compositions for treating inflammatory disorders |
| AU2004251599A1 (en) | 2003-05-20 | 2005-01-06 | Transtech Pharma, Inc. | Rage antagonists as agents to reverse amyloidosis and diseases associated therewith |
| UA89481C2 (uk) | 2003-09-30 | 2010-02-10 | Центокор, Инк. | Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування |
| CA2575830A1 (en) * | 2004-08-03 | 2006-02-16 | Transtech Pharma, Inc. | Rage fusion proteins and methods of use |
| US7393662B2 (en) * | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
-
2005
- 2005-09-27 CA CA002581505A patent/CA2581505A1/en not_active Abandoned
- 2005-09-27 JP JP2007533727A patent/JP2008537874A/ja active Pending
- 2005-09-27 AU AU2005289594A patent/AU2005289594B2/en not_active Ceased
- 2005-09-27 EP EP05815388A patent/EP1799700A4/en not_active Withdrawn
- 2005-09-27 WO PCT/US2005/034502 patent/WO2006036922A2/en not_active Ceased
- 2005-09-27 US US11/235,776 patent/US20060084145A1/en not_active Abandoned
-
2008
- 2008-07-17 US US12/174,677 patent/US8043616B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008537874A5 (enExample) | ||
| CN107759694B (zh) | 双特异性抗体及其制备方法与用途 | |
| US11111305B2 (en) | Method of using a bispecific antibody to conditionally inhibit a receptor signaling complex | |
| EP4186926A1 (en) | Ccr8 antibody and application thereof | |
| EP2314316A1 (en) | Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors | |
| EP3837283B1 (en) | Anti-il1rap antibody compositions | |
| CN113811549A (zh) | 非靶向和靶向性il-10 fc融合蛋白 | |
| EP3119806B1 (en) | Il-21 antibodies | |
| CN104144700B (zh) | 抗CD1d的抗体 | |
| JP2017503511A (ja) | 内在化部分 | |
| WO2018032638A1 (zh) | 用于构建融合蛋白的连接肽 | |
| EA021669B1 (ru) | Нейтрализующие антитела человека против b7rp1 | |
| RU2719158C2 (ru) | Антитело к epha4 | |
| TWI889705B (zh) | Gipr抗體及其與glp-1的融合蛋白質，以及其藥物組合物和應用 | |
| CA3119498A1 (en) | Methods for treating hepcidin-mediated disorders | |
| KR20190072616A (ko) | 면역글로불린 및 이의 용도 | |
| BRPI0707425A2 (pt) | construção de anticorpo de domìnio, molécula isolada de ácido nucleico, composição farmacêutica, e, métodos para detectar tnf-alfa humano em uma amostra, e para tratar um distúrbio | |
| TW202337912A (zh) | 四面體抗體 | |
| CN114874333B (zh) | 一种生长激素融合蛋白及其应用 | |
| EP3808771A1 (en) | Gipr antibody and glp-1 fusion protein thereof, and pharmaceutical composition and application thereof | |
| JP6959229B2 (ja) | 一本鎖ｇｉｔｒ受容体アゴニストタンパク質 | |
| CN114340737A (zh) | 激活性抗gal9结合分子 | |
| CN120225564A (zh) | 人源化抗il-1r3抗体及其使用方法 | |
| US12221488B2 (en) | APJ antibody, fusion protein thereof with Elabela, and pharmaceutical compositions and use thereofus01 | |
| JP5174022B2 (ja) | 膵臓β細胞増加促進剤及び膵臓β細胞増加促進組成物 |